A Community Study of Borrelia burgdorferi Antibodies among Individuals with Prior Lyme Disease in Endemic Areas
Authors:
- Barbara StrobinoBSBarbara Strobino
- Katja SteinhagenKSKatja Steinhagen
- Wolfgang MeyerWMWolfgang Meyer
- Thomas ScheperTSThomas Scheper
- Sandra SaschenbreckerSSSandra Saschenbrecker
- Wolfgang SchlumbergerWSWolfgang Schlumberger
- Winfried StöckerWSWinfried Stöcker
- Andrea GaitoAGAndrea Gaito
- Brian A. FallonBFBrian A. Fallon
Open Access
- 19 June 2018
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 6 (2) , 69
Abstract
The objective was to examine the prevalence of Borrelia antibodies among symptomatic individuals with recent and past Lyme disease in endemic communities using standard assays and novel assays employing next-generation antigenic substrates. Single- and two-tiered algorithms included different anti-Borrelia ELISAs and immunoblots. Antibody prevalence was examined in sera from 32 individuals with recent erythema migrans (EM), 335 individuals with persistent symptoms following treatment for Lyme disease (PTLS), and 41 community controls without a history of Lyme disease. Among convalescent EM cases, sensitivity was highest using the C6 ELISA (93.8%) compared to other single assays; specificity was 92.7% for the C6 ELISA vs. 85.4–97.6% for other assays. The two-tiered ELISA-EUROLINE IgG immunoblot combinations enhanced case detection substantially compared to the respective ELISA-IgG Western blot combinations (75.0% vs. 34.4%) despite similar specificity (95.1% vs. 97.6%, respectively). For PTLS cohorts, two-tier ELISA-IgG-blot positivity ranged from 10.1% to 47.4%, depending upon assay combination, time from initial infection, and clinical history. For controls, the two-tier positivity rate was 0–14.6% across assays. A two-tier algorithm of two-ELISA assays yielded a high positivity rate of 87.5% among convalescent EM cases with specificity of 92.7%. For convalescent EM, combinations of the C6 ELISA with a second-tier ELISA or line blot may provide useful alternatives to WB-based testing algorithms.Keywords
Funding Information
- Steven and Alexandra Cohen Foundation (903-2795)
- EuroImmun (n/a)
- Columbia Lyme & Tick-borne Diseases Research Center established by Global Lyme Alliance and the Lyme Disease Association (n/a)
This publication has 37 references indexed in Scilit:
- Correction: Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated InfectionPLOS ONE, 2012
- Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated InfectionPLOS ONE, 2012
- Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblotsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- 2‐Tiered Antibody Testing for Early and Late Lyme Disease Using Only an Immunoglobulin G Blot with the Addition of a VlsE Band as the Second‐Tier TestClinical Infectious Diseases, 2010
- Evaluation of the Recombinant VlsE-Based Liaison Chemiluminescence Immunoassay for Detection ofBorrelia burgdorferiand Diagnosis of Lyme DiseaseClinical and Vaccine Immunology, 2008
- Prospective Study of Serologic Tests for Lyme DiseaseClinical Infectious Diseases, 2008
- Editorial Commentary:Laboratory Testing for Lyme Disease: Time for a Change?Clinical Infectious Diseases, 2008
- The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Improvement of Lyme Borreliosis Serodiagnosis by a Newly Developed Recombinant Immunoglobulin G (IgG) and IgM Line Immunoblot Assay and Addition of VlsE and DbpA HomologuesJournal of Clinical Microbiology, 2005
- A Limitation of 2-Stage Serological Testing for Lyme Disease: Enzyme Immunoassay and Immunoblot Assay Are Not Independent TestsClinical Infectious Diseases, 2000